A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
Study Identifier:
SYNT001-103
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Skin, Hair & Nails - Other
- Unmapped
Study Drug
- Drug: ALXN1830
Date
Jul 2017 - Jan 2019
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Skin, Hair & Nails - Other
- Unmapped
Study Drug
- Drug: ALXN1830
Date
Jul 2017 - Jan 2019
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
This was a multicenter, open-label safety study to determine the dose regimen of SYNT001 (ALXN1830) administered intravenously in participants with pemphigus (vulgaris or foliaceus).
Trial Locations
Location
Status
Location
Alexion Study Site
Chapel Hill, North Carolina, United States, 27516
Status
N/A
Location
Alexion Study Site
Durham, North Carolina, United States, 27710
Status
N/A
Location
Alexion Study Site
Philadelphia, Pennsylvania, United States, 19104
Status
N/A